146 related articles for article (PubMed ID: 27063332)
1. African horse sickness virus serotype 4 antigens, VP1-1, VP2-2, VP4, VP7 and NS3, induce cytotoxic T cell responses in vitro.
Faber FE; van Kleef M; Tshilwane SI; Pretorius A
Virus Res; 2016 Jul; 220():12-20. PubMed ID: 27063332
[TBL] [Abstract][Full Text] [Related]
2. An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses.
El Garch H; Crafford JE; Amouyal P; Durand PY; Edlund Toulemonde C; Lemaitre L; Cozette V; Guthrie A; Minke JM
Vet Immunol Immunopathol; 2012 Sep; 149(1-2):76-85. PubMed ID: 22763149
[TBL] [Abstract][Full Text] [Related]
3. VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV.
van de Water SG; van Gennip RG; Potgieter CA; Wright IM; van Rijn PA
J Virol; 2015 Sep; 89(17):8764-72. PubMed ID: 26063433
[TBL] [Abstract][Full Text] [Related]
4. Identification of T cell and linear B cell epitopes on African horse sickness virus serotype 4 proteins VP1-1, VP2, VP4, VP7 and NS3.
Faber E; van Schalkwyk A; Ivy Tshilwane S; Van Kleef M; Pretorius A
Vaccine; 2024 Jan; 42(2):136-145. PubMed ID: 38097459
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination.
Manning NM; Bachanek-Bankowska K; Mertens PPC; Castillo-Olivares J
Vaccine; 2017 Oct; 35(44):6024-6029. PubMed ID: 28438410
[TBL] [Abstract][Full Text] [Related]
6. Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus.
Guthrie AJ; Quan M; Lourens CW; Audonnet JC; Minke JM; Yao J; He L; Nordgren R; Gardner IA; Maclachlan NJ
Vaccine; 2009 Jul; 27(33):4434-8. PubMed ID: 19490959
[TBL] [Abstract][Full Text] [Related]
7. Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge.
Roy P; Bishop DH; Howard S; Aitchison H; Erasmus B
J Gen Virol; 1996 Sep; 77 ( Pt 9)():2053-7. PubMed ID: 8811002
[TBL] [Abstract][Full Text] [Related]
8. The use of African horse sickness virus VP7 antigen, synthesised in bacteria, and anti-VP7 monoclonal antibodies in a competitive ELISA.
Wade-Evans AM; Woolhouse T; O'Hara R; Hamblin C
J Virol Methods; 1993 Dec; 45(2):179-88. PubMed ID: 8113344
[TBL] [Abstract][Full Text] [Related]
9. Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7.
Martínez-Torrecuadrada JL; Díaz-Laviada M; Roy P; Sánchez C; Vela C; Sánchez-Vizcaíno JM; Casal JI
J Gen Virol; 1996 Jun; 77 ( Pt 6)():1211-21. PubMed ID: 8683209
[TBL] [Abstract][Full Text] [Related]
10. African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3/NS3a protein is not virulent and a safe promising AHS Disabled Infectious Single Animal (DISA) vaccine platform.
van Rijn PA; Maris-Veldhuis MA; Potgieter CA; van Gennip RGP
Vaccine; 2018 Apr; 36(15):1925-1933. PubMed ID: 29525278
[TBL] [Abstract][Full Text] [Related]
11. Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challenge.
Calvo-Pinilla E; de la Poza F; Gubbins S; Mertens PP; Ortego J; Castillo-Olivares J
Antiviral Res; 2015 Apr; 116():27-33. PubMed ID: 25643968
[TBL] [Abstract][Full Text] [Related]
12. Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation.
Calvo-Pinilla E; de la Poza F; Gubbins S; Mertens PP; Ortego J; Castillo-Olivares J
Virus Res; 2014 Feb; 180():23-30. PubMed ID: 24333835
[TBL] [Abstract][Full Text] [Related]
13. Structural Protein VP2 of African Horse Sickness Virus Is Not Essential for Virus Replication In Vitro.
van Gennip RGP; van de Water SGP; Potgieter CA; van Rijn PA
J Virol; 2017 Feb; 91(4):. PubMed ID: 27903804
[TBL] [Abstract][Full Text] [Related]
14. Assembly of Replication-Incompetent African Horse Sickness Virus Particles: Rational Design of Vaccines for All Serotypes.
Lulla V; Lulla A; Wernike K; Aebischer A; Beer M; Roy P
J Virol; 2016 Aug; 90(16):7405-7414. PubMed ID: 27279609
[TBL] [Abstract][Full Text] [Related]
15. African horsesickness virus VP7 sub-unit vaccine protects mice against a lethal, heterologous serotype challenge.
Wade-Evans AM; Pullen L; Hamblin C; O'Hara R; Burroughs JN; Mertens PP
J Gen Virol; 1997 Jul; 78 ( Pt 7)():1611-6. PubMed ID: 9225037
[TBL] [Abstract][Full Text] [Related]
16. The use of African horse sickness virus NS3 protein, expressed in bacteria, as a marker to differentiate infected from vaccinated horses.
Laviada MD; Roy P; Sánchez-Vizcaíno JM; Casal JI
Virus Res; 1995 Oct; 38(2-3):205-18. PubMed ID: 8578859
[TBL] [Abstract][Full Text] [Related]
17. The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host.
Calvo-Pinilla E; Gubbins S; Mertens P; Ortego J; Castillo-Olivares J
Antiviral Res; 2018 Jun; 154():132-139. PubMed ID: 29678552
[TBL] [Abstract][Full Text] [Related]
18. Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus Ankara.
Marín-López A; Barreiro-Piñeiro N; Utrilla-Trigo S; Barriales D; Benavente J; Nogales A; Martínez-Costas J; Ortego J; Calvo-Pinilla E
Vaccine; 2020 Jan; 38(4):882-889. PubMed ID: 31708178
[TBL] [Abstract][Full Text] [Related]
19. A correlation between capsid protein VP2 and the plaque morphology of African horse sickness virus in cell culture.
Schade-Weskott ML; van Schalkwyk A; Koekemoer JJO
Virus Genes; 2018 Aug; 54(4):527-535. PubMed ID: 29730763
[TBL] [Abstract][Full Text] [Related]
20. Preparation of recombinant African horse sickness virus VP7 antigen via a simple method and validation of a VP7-based indirect ELISA for the detection of group-specific IgG antibodies in horse sera.
Maree S; Paweska JT
J Virol Methods; 2005 Apr; 125(1):55-65. PubMed ID: 15737417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
